Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

- CAPACITY shows potential for pirfenidone role in treatment of patients with IPF -

- Ground-breaking data from INFORM-1 study; first all-oral combination in HCV -

- Strong data from 14-day triple combination study of ITMN-191 in HCV -

BRISBANE, Calif., April 30 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the first quarter ended March 31, 2009. InterMune reported a net loss for the first quarter of 2009 of $42.0 million, or $1.03 per share, compared with a net loss of $29.1 million, or $0.75 per share, in the first quarter of 2008.

Dan Welch, Chairman, President and Chief Executive Officer of InterMune, said, "The first months of 2009 were an exceptionally productive period for InterMune. We began the year by reporting strong data from our triple combination study of ITMN-191 (R7227) in hepatitis C virus (HCV) patients and shortly thereafter reported results from our Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF). In April, we reported with Roche and Pharmasset exciting new data from INFORM-1, the first-ever combination of a nucleoside polymerase inhibitor and protease inhibitor in the absence of interferon in patients infected with HCV. We also recently strengthened our balance sheet by raising $63 million in cash and by exchanging $32 million in convertible debt for shares of our common stock. The remainder of 2009 is expected to be as productive for pirfenidone and ITMN-191 and we look forward to sharing those results as they develop."

InterMune reported total revenue in the first quarter of 2009 of $6.9 million, compared with total revenue of $9.3 million in the first quarter of 2008. Total revenue in the first quarter of 2009 primarily consisted of Actimmune(R) (in
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
(Date:5/21/2013)... Boston, MA (PRWEB) May 21, 2013 ... unified communications platform, Microsoft Lync, for customers in Canada. ... communications software and will allow businesses and organizations ... Last month, SoundConnect released Lync in the United ... US, paired with the product release in Canada, SoundConnect ...
Breaking Biology Technology:MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2SoundConnect Announces Microsoft Lync Release in Canada 2SoundConnect Announces Microsoft Lync Release in Canada 3
... strain of virus broadens government readiness program -, ... the vaccines division of sanofi-aventis Group, announced,today that the ... H5N1 bulk vaccine antigen to produce approximately 38.5 million,doses ... avian influenza. Sanofi,Pasteur has a multi- year contract with ...
... CHINA, April 28 Simcere,Pharmaceutical Group (NYSE: ... generic pharmaceuticals and manufacturer of the patented,anti-cancer biotech ... has been,informed that one of its existing shareholders, ... beneficially owned by 15,individuals, including certain senior management ...
... 28 MBF Healthcare,Acquisition Corp. (Amex: MBH ... today that it and Critical Homecare,Solutions Holdings, Inc. ... therapy and specialty infusion services, are,scheduled to present ... Annual Deutsche,Bank Healthcare Conference in Boston, MA. On ...
Cached Biology Technology:U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 2U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 3U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile 4Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 2Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder 3MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 2MBF Healthcare Acquisition Corp. and Critical Homecare Solutions Holdings, Inc. to Present at the 33rd Annual Deutsche Bank Healthcare Conference 3
(Date:5/19/2013)... Researchers have engineered a strain of electricity-producing bacteria that ... donor and carbon dioxide as its sole source of ... report their findings at the 113th General Meeting of ... first result of current production solely on hydrogen," says ... with his co-authors are part of the Lovley Lab ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... Bethesda, MD (May 18, 2013) The AGA Research ... research into the relationship between the gut microbiota, one ... health and disease. , The AGA Research Awards ... colleagues from Massachusetts General Hospital and Harvard Medical School, ... Award recipient. Dr. Chan will receive $25,000 of funding, ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New gut microbiome research to explore red meat -- colorectal cancer pathway 2
... Reportlinker.com announces that a new market research report is ... Markets: Microarrays and Lab-on-a-Chip http://www.reportlinker.com/p0170497/Global-Biochip-Markets-Microarrays-and-Lab-on-a-Chip.html ... STUDY GOALS AND OBJECTIVES BCC,s ... of current and emerging biochip technologies and products, and ...
... of Escherichia coli causing a severe illness called hemolytic-uremic syndrome ... killed more than 20 people and sickened more than 2,000. ... strain of E. coli O104:H4 that produces a ... E. coli O157:H7. Two isolates from this outbreak ...
... Ore. June 6, 2011. Sustainability is the theme for ... Society, scheduled to meet in Portland June 19 to ... others from academia, government, non-profit groups, and private industry ... products industry and share information about innovations in the ...
Cached Biology News:Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15Two isolates from E. coli outbreak available 2
The novel and unique HCTplus delivers unmatched information-rich data-dependent LC/MSn data for todays challenge in proteomics and metabonomics work....
... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...
... short years since publication of the best-selling ... acclaimed Protein Protocols Handbook, there have been ... In recognition of the level of attention ... of new methodologies directed to study them, ...
... silencing experiments often call for critical, ... Transfection Agent refines siRNA transfection protocols ... lipid-based formulation can be used to ... are subcultured without increased cytotoxicity. ...
Biology Products: